Blood test to predict immunotherapy response in rare kidney cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether a simple blood test that tracks tumor DNA (called ctDNA) can help predict how well immunotherapy will work for people with non-clear cell kidney cancer. If you are about to start immunotherapy for advanced disease, this study could help your doctor better understand your treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 years or older.
- You must have a type of kidney cancer called non-clear cell renal cell carcinoma (that includes papillary, chromophobe, collecting duct, and other rare types).
- The cancer must be advanced or have spread, and not removable by surgery.
- Your doctor must plan to start you on a treatment that includes an immunotherapy drug (a checkpoint inhibitor) — alone, combined with another drug, or with targeted therapy.
- You should feel reasonably well: able to care for yourself, even if you need to rest some of the day.
- You must be willing to provide blood and tumor samples for the study's special DNA testing (ctDNA monitoring).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study uses a special CT scan to see how well your first treatment for kidney cancer that has spread is working. It looks at people with clear cell renal cell carcinoma who are starting immunotherapy combined with a targeted drug or two immunotherapy drugs.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial tests an experimental therapy using special immune cells engineered to target a protein called CD70 on kidney cancer cells. It may help patients whose cancer has returned or spread after previous treatment.
Hear when a new Non-Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.